Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

Martha Q. Lacy; Susanna Jacobus; Emily A. Blood; Neil E. Kay; S. Vincent Rajkumar; Philip R. Greipp

doi:10.1016/j.leukres.2009.01.020

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

Martha Q. Lacy, Susanna Jacobus, Emily A. Blood, Neil E. Kay, S. Vincent Rajkumar, Philip R. Greipp

Hematology

Research output: Contribution to journal › Article › peer-review

38 Scopus citations

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

Original language	English (US)
Pages (from-to)	1485-1489
Number of pages	5
Journal	Leukemia Research
Volume	33
Issue number	11
DOIs	https://doi.org/10.1016/j.leukres.2009.01.020
State	Published - Nov 2009

Keywords

Immunomodulatory therapy
Interleukin-12
Multiple myeloma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2009.01.020

Cite this

@article{2dfa191af40542f6ac4790d4cfc3124b,

title = "Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group",

abstract = "The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.",

keywords = "Immunomodulatory therapy, Interleukin-12, Multiple myeloma",

author = "Lacy, {Martha Q.} and Susanna Jacobus and Blood, {Emily A.} and Kay, {Neil E.} and Rajkumar, {S. Vincent} and Greipp, {Philip R.}",

note = "Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. ",

year = "2009",

month = nov,

doi = "10.1016/j.leukres.2009.01.020",

language = "English (US)",

volume = "33",

pages = "1485--1489",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "11",

}

TY - JOUR

T1 - Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96)

T2 - A trial of the Eastern Cooperative Oncology Group

AU - Lacy, Martha Q.

AU - Jacobus, Susanna

AU - Blood, Emily A.

AU - Kay, Neil E.

AU - Rajkumar, S. Vincent

AU - Greipp, Philip R.

N1 - Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2009/11

Y1 - 2009/11

N2 - The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

AB - The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks. The trial was modified due to toxicity after the first 16 patients. IL-12 was given 300 ng/kg subcutaneously twice weekly for 24 weeks. Of 48 eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non-hematologic toxicity (31% with IL-12 subcutaneously and 63% with IL-12 intravenously) was observed.

KW - Immunomodulatory therapy

KW - Interleukin-12

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=68649089730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68649089730&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.01.020

DO - 10.1016/j.leukres.2009.01.020

M3 - Article

C2 - 19243818

AN - SCOPUS:68649089730

SN - 0145-2126

VL - 33

SP - 1485

EP - 1489

JO - Leukemia Research

JF - Leukemia Research

IS - 11

ER -

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this